Media coverage about Blueprint Medicines Corporation (NASDAQ:BPMC) has trended somewhat positive on Sunday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Blueprint Medicines Corporation earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the next few days.
A number of brokerages have commented on BPMC. Goldman Sachs Group, Inc. (The) upgraded shares of Blueprint Medicines Corporation from a “neutral” rating to a “buy” rating and set a $52.00 target price on the stock in a research note on Monday, March 13th. Zacks Investment Research downgraded shares of Blueprint Medicines Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, April 18th. Jefferies Group LLC upped their target price on shares of Blueprint Medicines Corporation from $42.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, May 4th. Canaccord Genuity upped their target price on shares of Blueprint Medicines Corporation from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, April 4th. Finally, JMP Securities began coverage on shares of Blueprint Medicines Corporation in a research note on Wednesday, March 22nd. They issued an “outperform” rating and a $46.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Blueprint Medicines Corporation presently has a consensus rating of “Buy” and a consensus target price of $47.40.
Blueprint Medicines Corporation (NASDAQ BPMC) opened at 50.00 on Friday. Blueprint Medicines Corporation has a 52 week low of $17.35 and a 52 week high of $50.14. The company’s market capitalization is $1.66 billion. The firm has a 50-day moving average of $39.35 and a 200-day moving average of $36.91.
Blueprint Medicines Corporation (NASDAQ:BPMC) last released its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by $0.11. The company had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $6.02 million. Blueprint Medicines Corporation had a negative net margin of 317.57% and a negative return on equity of 55.58%. Blueprint Medicines Corporation’s revenue was down 14.9% on a year-over-year basis. During the same period last year, the firm posted ($0.57) earnings per share. Analysts anticipate that Blueprint Medicines Corporation will post ($3.32) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was first reported by sleekmoney and is the property of of sleekmoney. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://sleekmoney.com/blueprint-medicines-corporation-bpmc-getting-somewhat-favorable-media-coverage-study-shows/1938611.html.
About Blueprint Medicines Corporation
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/blueprint-medicines-corporation-bpmc-getting-somewhat-favorable-media-coverage-study-shows/1938611.html
Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.